|
|
 Previous Article | Table of Contents | Next Article 
Expression of the bcl-2 gene in human multiple myeloma cell lines and
normal plasma cells
M Pettersson, H Jernberg-Wiklund, LG Larsson, C Sundstrom, I Givol, Y Tsujimoto and K Nilsson
Department of Pathology, University Hospital, Uppsala, Sweden.
The bcl-2 gene, encoding a mitochondrial membrane protein suggested to play
an important role in cell survival, is translocated into the Ig loci in
about 80% of human follicular lymphomas, which results in a high level of
expression. This report shows that bcl-2 was expressed in eight of eight
human multiple myeloma cell lines and in normal lymph node and bone marrow
plasma cells. In the majority of the myeloma lines, the level of expression
was comparable with that observed in Karpas 422, a follicular lymphoma cell
line carrying a 14;18 translocation of the bcl-2 gene. DNA rearrangements
of the bcl-2 locus were evident in only one of the myeloma cell lines,
U-266-1970. In this cell line, which exhibited the highest bcl-2
expression, a fourfold increased copy number of the bcl-2 gene was
estimated by Southern analysis. This amplification was lost in cells of
later passages (U-266- 1984), suggesting that bcl-2 might possibly have
played a role in the tumor development in vivo. Our results are in contrast
to previous observations in murine plasmacytoma, in which bcl-2 was shown
to be silent. The results also contradict the published observation that
bcl- 2 is not expressed at terminal stages of B-cell differentiation. It is
at present unclear whether the high expression of bcl-2 in human myeloma is
the result of a deregulated expression associated with the malignant
phenotype or a mere reflection of the bcl-2 expression typical of normal
plasma cells.
Volume 79,
Issue 2,
pp. 495-502,
01/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. R. Berenson, J. Matous, R. A. Swift, R. Mapes, B. Morrison, and H. S. Yeh
A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
Clin. Cancer Res.,
March 15, 2007;
13(6):
1762 - 1768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bhardwaj, G. Sethi, S. Vadhan-Raj,, C. Bueso-Ramos, Y. Takada, U. Gaur, A. S. Nair, S. Shishodia, and B. B. Aggarwal
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-{kappa}B-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells
Blood,
March 15, 2007;
109(6):
2293 - 2302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
298 - 327.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Triplett and F. M. Pavalko
Disruption of {alpha}-actinin-integrin interactions at focal adhesions renders osteoblasts susceptible to apoptosis
Am J Physiol Cell Physiol,
November 1, 2006;
291(5):
C909 - C921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gerl and D. L. Vaux
Apoptosis in the development and treatment of cancer
Carcinogenesis,
February 1, 2005;
26(2):
263 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-Y. Pei, Y. Dai, and S. Grant
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism
Mol. Cancer Ther.,
December 1, 2004;
3(12):
1513 - 1524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Bharti, S. Shishodia, J. M. Reuben, D. Weber, R. Alexanian, S. Raj-Vadhan, Z. Estrov, M. Talpaz, and B. B. Aggarwal
Nuclear factor-{kappa}B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
Blood,
April 15, 2004;
103(8):
3175 - 3184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Beaupre, E. Cepero, E. A. Obeng, L. H. Boise, and M. G. Lichtenheld
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways
Mol. Cancer Ther.,
February 1, 2004;
3(2):
179 - 186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson
Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis
J. Clin. Oncol.,
November 15, 2003;
21(22):
4239 - 4247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Bharti, N. Donato, and B. B. Aggarwal
Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells
J. Immunol.,
October 1, 2003;
171(7):
3863 - 3871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Bharti, N. Donato, S. Singh, and B. B. Aggarwal
Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa Balpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis
Blood,
February 1, 2003;
101(3):
1053 - 1062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Renner, J. Weisz, S. Krajewski, M. Krajewska, J. C. Reed, and A. Lichtenstein
Expression of BAX in Plasma Cell Dyscrasias
Clin. Cancer Res.,
June 1, 2000;
6(6):
2371 - 2380.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Feinman, J. Koury, M. Thames, B. Barlogie, J. Epstein, and D. S. Siegel
Role of NF-kappa B in the Rescue of Multiple Myeloma Cells From Glucocorticoid-Induced Apoptosis by Bcl-2
Blood,
May 1, 1999;
93(9):
3044 - 3052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Spets, P. Georgii-Hemming, J. Siljason, K. Nilsson, and H. Jernberg-Wiklund
Fas/APO-1 (CD95)-Mediated Apoptosis Is Activated by Interferon-gamma and Interferon-alpha in Interleukin-6 (IL-6)-Dependent and IL-6-Independent Multiple Myeloma Cell Lines
Blood,
October 15, 1998;
92(8):
2914 - 2923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Siegel, X. Zhang, R. Feinman, T. Teitz, A. Zelenetz, V. M. Richon, R. A. Rifkind, P. A. Marks, and J. Michaeli
Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells
PNAS,
January 6, 1998;
95(1):
162 - 166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood,
January 1, 1998;
91(1):
3 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Monni, H. Joensuu, K. Franssila, J. Klefstrom, K. Alitalo, and S. Knuutila
BCL2 Overexpression Associated With Chromosomal Amplification in Diffuse Large B-Cell Lymphoma
Blood,
August 1, 1997;
90(3):
1168 - 1174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nishida, A. Tamura, N. Nakazawa, Y. Ueda, T. Abe, F. Matsuda, K. Kashima, and M. Taniwaki
The Ig Heavy Chain Gene Is Frequently Involved in Chromosomal Translocations in Multiple Myeloma and Plasma Cell Leukemia as Detected by In Situ Hybridization
Blood,
July 15, 1997;
90(2):
526 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
